Free Trial
NASDAQ:CRBP

Corbus Pharmaceuticals Q2 2025 Earnings Report

Corbus Pharmaceuticals logo
$7.54 +0.24 (+3.29%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$7.46 -0.09 (-1.13%)
As of 07/8/2025 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corbus Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$1.35
Beat/Miss
N/A
One Year Ago EPS
N/A

Corbus Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Corbus Pharmaceuticals Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Corbus Pharmaceuticals Earnings Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
See More Corbus Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Corbus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corbus Pharmaceuticals and other key companies, straight to your email.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals (NASDAQ:CRBP) (NASDAQ:CRBP) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for patients with rare inflammatory and fibrotic diseases. Headquartered in Norwood, Massachusetts, Corbus applies its expertise in the endocannabinoid system to advance a pipeline of small-molecule drug candidates designed to modulate immune responses and reduce chronic inflammation and fibrosis.

The company’s lead investigational therapy, lenabasum, is an oral, selective cannabinoid type 2 (CB2) receptor agonist. Lenabasum is being evaluated in Phase 3 trials for systemic sclerosis and dermatomyositis, two debilitating autoimmune conditions characterized by inflammation and tissue scarring. Corbus is also advancing additional programs—CRB-601 and CRB-602—aimed at addressing unmet medical needs in conditions where dysregulation of innate immune signaling plays a central role.

Founded in 2006 under its former name, CB Therapeutics, the company rebranded to Corbus Pharmaceuticals in 2013 following its initial public offering. Over the years, Corbus has established research collaborations with academic institutions and clinical centers across North America and Europe. These partnerships support its rigorous clinical trial programs and facilitate access to patient populations affected by rare diseases.

Corbus is led by President and Chief Financial Officer Donald F. McCaffrey, who brings more than two decades of experience in biotechnology finance and operations. The company’s executive team and board of directors comprise seasoned professionals in drug development, regulatory affairs, and commercial strategy, all united by a commitment to bringing new therapies to patients with few treatment options.

View Corbus Pharmaceuticals Profile

More Earnings Resources from MarketBeat